Akynzeo (netupitant/palonosetron) prior authorization
Customize your policy alerts
Sign up for all harvard pilgrim health care policy alerts
Know when harvard pilgrim health care releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria for coverage of Akynzeo (netupitant/palonosetron) for prevention of chemotherapy-induced nausea and vomiting in adult members of Harvard Pilgrim and Tufts commercial products.
Administrative update to add limitation statement for non-formulary medication request.
Administrative update to remove Carelink from Medical Necessity Guideline template.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.